Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig + FOLFIRI + Bevacizumab in Metastatic Colorectal Cancer
NCT06792695Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Countries
- 12
01
Overview
A Phase 2 trial of volrustomig in metastatic colorectal cancer (mCRC), sponsored by AstraZeneca. Started Mar 2025; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06792695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792695.